Janssen strengthens submission in light chain amyloidosis

8 December 2020

janssen_image_only_use_for_janssen_article_large

The Johnson & Johnson (NYSE: JNJ) subsidiary Janssen has presented new data from the Phase III ANDROMEDA study, which evaluated Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a treatment for patients with light chain (AL) amyloidosis.

This rare disease is associated with deterioration of vital organs, most notably the heart, kidneys and liver, and has no currently approved therapies.

The data, which were featured in an oral presentation at the American Society of Hematology (ASH) 2020 Annual Meeting, showed a significantly higher complete hematologic response rate with Darzalex Faspro treatment in patients with this potentially fatal blood disorder compared to standard regimen and consistent decreases in markers of disease, indicative of deep hematologic responses.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK